TREATMENT WITH VIVITROL TO REDUCE SELF-BITING BEHAVIOR IN ADULT RHESUS MACAQUES

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 自我伤害行为（SIB）可以定义为任何导致组织损伤的自我导向行为。这种情况发生在大约5-13%的圈养恒河猴种群中，自咬是最常见的行为表现。此外，SIB是一个重要的人类健康问题，有趣的是，它发生在4%的普通公众中。目前，对于人或非人灵长类动物SIB没有广泛接受的治疗。然而，对人类和非人类灵长类动物的研究表明，用于治疗酒精中毒和药物滥用的治疗药物，如口服盐酸纳曲酮，可有效减少SIB的发生。 迄今为止，还没有研究检查Vivitrol（一种长效30天注射用纳洛酮）治疗人类或非人类灵长类动物SIB的价值。一项使用Vivitrol治疗SIB的重点研究可能会开启Vivitrol在研究机构和公众中的新用途的探索。方法：第1组（n=4）：成年雄性恒河猴（Macaca mulatta）参加为期4周的药代动力学研究。注射后21-28天维持2 ng/ml血浆的治疗水平。第2组（n=10）：将记录有自伤行为的成年雄性和雌性猕猴纳入治疗研究。在前四周阶段，建立基线行为。注射两次Vivitrol，注射间隔四周。该阶段之后是额外的4周治疗后基线期。所有观察结果均通过视频记录和编码（观察者9 XT）根据已建立的行为谱进行。 在每次Vivitrol注射时和研究结束前每隔7天采集血样，用于治疗范围数据分析。结果：目前正在分析观察数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Introduction: Self-injurious behavior (SIB) may be defined as any self-directed behavior that results in tissue injury. The condition occurs in approximately 5-13% of the captive rhesus macaque population with self-biting being the most common expression of the behavior. Additionally, SIB is a significant human health problem, which interestingly occurs in 4% of the general public. Currently, there are no widely accepted treatments for human or nonhuman primate SIB. However, studies with human and nonhuman primates have shown that therapeutic drugs used to treat alcoholism and drug abuse, such as oral naltrexone hydrochloride, are effective in reducing the occurrence of SIB. To date, there have been no studies examining the value of Vivitrol, a long-acting 30 day injectable naltrexone, for the treatment of human or nonhuman primate SIB. A focused study using Vivitrol for SIB may open the exploration of a novel use for Vivitrol in both research facilities and the general public. Methods: Group 1 (n=4): Adult male rhesus macaques (Macaca mulatta) were enrolled in a 4-week pharmacokinetic study. Therapeutic levels of 2ng/ml plasma were maintained 21-28 days post-injection. Group 2 (n=10): Adult male and female macaques with documented self-injurious behavior were enrolled in a treatment study. In the first four week phase baseline behavior was established. Two injections of Vivitrol were administered with a four week interval between injections. This phase was followed by an additional 4 week post-treatment baseline period. All observations were made through video recording and coding (Observer 9XT) according to an established ethogram. Blood samples were collected at the time of each Vivitrol injection and at seven day intervals until the end of the study for therapeutic range data analysis. Results: Observational data is currently being analyzed.